Posted by Michael Wonder on 22 Jul 2025
Johnson & Johnson seeks first icotrokinra US FDA approval aiming to revolutionise treatment paradigm for adults and adolescents with plaque psoriasis
21 July 2025 - Icotrokinra is a first in class investigational targeted oral peptide that selectively blocks the IL-23 receptor.
Johnson & Johnson today announced the submission of a new drug application to the US FDA seeking the first approval of icotrokinra, a first in class investigational targeted oral peptide that selectively blocks the IL-23 receptor for the treatment of adults and paediatric patients 12 years of age and older with moderate to severe plaque psoriasis.
